ERBB2 and breast cancer: In a metanalysis, it was highlighted that high pretreatment NLR was an independent poor prognostic factor for overall survival (OS) and progression-free survival (PFS) in all-stage BC, with the strongest association in the HR+/HER2- subgroup (13).